Confidential Pfizer Documents obtained by Project Veritas reveal the pharmaceutical company had evidence in early 2022 suggesting an increased risk of myocarditis, or heart inflammation, following vaccination with its COVID-19 vaccine. Yet, the pharmaceutical giant failed to include the condition as an adverse event of its vaccine.
In a 48-page document, Pfizer scientists claimed inflammation of the heart following vaccination was not a result of cardiotoxicity but suggested lipid nanoparticles in the messenger RNA vaccine that deliver the spike protein may trigger the immune system causing myocarditis.
“Although the BNT162b2 mRNA vaccine is optimized to reduce its detection by the innate immune system through the addition of nucleoside modifications and minimizing double-strand RNA impurity, it is possible, especially in certain individuals with genetic predisposition and underlying conditions, that the immune responses to mRNA may not be sufficiently turned down and drive the activation of an innate and adaptive immune response,” they wrote.
“This may lead to the excessive activation of proinflammatory cascades, which contribute to the development of myocarditis,” they added.
Myocarditis is heart muscle inflammation that can lead to cardiac arrhythmia and death. According to the National Organization for Rare Disorders, myocarditis can result from infections, but “more commonly, the myocarditis is a result of the body’s immune reaction to the initial heart damage.”
According to the most recent data from the Vaccine Adverse Event Reporting System, 25,487 cases of myocarditis and pericarditis were reported between Dec. 14, 2020, and March 10, 2023, following COVID-19 vaccination, with 19,349 cases attributed to Pfizer, 5,636 cases to Moderna, and 442 to Johnson & Johnson.
Although the Centers for Disease Control and Prevention acknowledged Pfizer’s COVID vaccine may cause myocarditis, Pfizer did not list myocarditis as an adverse event of its vaccine, according to documents obtained by Project Veritas.
Read the internal documents and communications obtained here and here.